C. Brock
Impact in
- Genetics top 1%
- Glioma Diagnosis and Treatment
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Cancer Genomics and Diagnostics 5
- Cancer, Hypoxia, and Metabolism 4
-
- PI3K/AKT/mTOR signaling in cancer 2
- Co-authors
- E.S. Newlands (10 shared papers)Stephen R. Wedge (2 shared papers)Richard T. Wheelhouse (1 shared paper)M. F. G. STEVENS (1 shared paper)Mark Bower (10 shared papers)Gordon Rustin (5 shared papers)Helen Evans (4 shared papers)M.G. Glaser (4 shared papers)
- Journals
- British Journal of Cancer (5 papers)Journal of Clinical Oncology (4 papers)European Journal of Cancer (2 papers)Cancer Treatment Reviews (1 paper)Cancer Chemotherapy and Pharmacology (1 paper)
- Partner nations
- United KingdomUnited StatesSwitzerland
In The Last Decade
C. Brock
32 papers receiving 1.8k citations
C. Brock's Hit Papers
Peers
Comparison fields: 5 of 108
- Genetics 630
- Cancer Research 209
- Radiology, Nuclear Medicine and Imaging 281
- Pulmonary and Respiratory Medicine 341
- Oncology 274
Countries citing papers authored by C. Brock
This map shows the geographic impact of C. Brock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Brock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Brock more than expected).
Fields of papers citing papers by C. Brock
This network shows the impact of papers produced by C. Brock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Brock. The network helps show where C. Brock may publish in the future.
Co-authors
The 25 scholars most cited alongside C. Brock, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials Hit paper breakdown → | 1997 | 676 |
| 2 | 1997 | 251 | |
| 3 | Phase I trial of temozolomide using an extended continuous oral schedule. | 1998 | 239 |
| 4 | 1996 | 138 | |
| 5 | 2000 | 99 | |
| 6 | 1997 | 90 | |
| 7 | 2003 | 82 | |
| 8 | 2001 | 66 | |
| 9 | 1999 | 54 | |
| 10 | 1998 | 26 | |
| 11 | 2002 | 24 | |
| 12 | 2004 | 22 | |
| 13 | 2004 | 18 | |
| 14 | 2006 | 17 | |
| 15 | 2005 | 16 | |
| 16 | 2014 | 12 | |
| 17 | 1997 | 12 | |
| 18 | 1997 | 10 | |
| 19 | 1997 | 10 | |
| 20 | 2002 | 10 |
About C. Brock
C. Brock is a scholar working on Cancer Research, Molecular Biology, Genetics, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine, having authored 33 papers that have together received 1.9k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (8 papers), Medical Imaging Techniques and Applications (6 papers), Cancer Genomics and Diagnostics (5 papers), Testicular diseases and treatments (4 papers), Gestational Trophoblastic Disease Studies (4 papers), Cancer, Hypoxia, and Metabolism (4 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). The work is most often cited by research in Genetics (630 citations), Cancer Research (209 citations), Radiology, Nuclear Medicine and Imaging (281 citations), Pulmonary and Respiratory Medicine (341 citations) and Oncology (274 citations). C. Brock has collaborated with scholars based in United Kingdom, United States and Switzerland. Frequent co-authors include E.S. Newlands, Stephen R. Wedge, Richard T. Wheelhouse, M. F. G. STEVENS, Mark Bower, Gordon Rustin, Helen Evans, M.G. Glaser, L. Holden and Richard H. J. Beǵent. Their work appears in journals such as British Journal of Cancer, Journal of Clinical Oncology, European Journal of Cancer, Cancer Treatment Reviews and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.